TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQX: MVMDF) (FRA: 20MP) is pleased to announce the successful completion of its pre-clinical pharmacokinetic study - IM032 - in male beagle dogs comparing intramuscular (“IM”) and subcutaneous (“SC”) dosing of Soluvec™ 1% with oral administration of commercially available branded ivermectin.
Mountain Valley MD Successfully Completes Pre-Clinical Pharmacokinetic Study For Soluvec™1%
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.